040 – Biogen faces another headwind with Zolgensma approval

Hi all, I’m back today talking about the approval of Avexis/Novartis’ gene therapy for spinal muscular atrophy, Zolgensma. I also talk about how I came to a conclusion about whether or not I should short Biogen.

Follow me on twitter @matthewlepoire
http://www.breakingbiotech.com
*this is not investment advice*

 

Novartis buys Avexis!

-Novartis buys gene therapy company, Avexis for $8.7 billion
http://investors.avexis.com/phoenix.zhtml?c=254285&p=irol-newsArticle&ID=2341482

-Spark is another gene therapy company I like, involved in hemophilia and eye-related blindness diseases
http://sparktx.com/

Follow me on twitter @matthewlepoire

 
%d bloggers like this: